Spots Global Cancer Trial Database for renal cell carcinoma (rcc)
Every month we try and update this database with for renal cell carcinoma (rcc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | NCT05846646 | Oligometastatic... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | NCT04375150 | Renal Cell Carc... | Tyrosine kinase... Immuno-oncology... | 20 Years - | Pfizer | |
| A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | NCT05468697 | Renal Cell Carc... | Belzutifan Palbociclib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | NCT04195750 | Carcinoma, Rena... | Belzutifan Everolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | NCT02178722 | Microsatellite-... Endometrial Can... Head and Neck C... Hepatocellular ... Gastric Cancer Lung Cancer Lymphoma Renal Cell Carc... Ovarian Cancer Solid Tumors UC (Urothelial ... Melanoma Bladder Cancer Triple Negative... | MK-3475 INCB024360 | 18 Years - | Incyte Corporation | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | NCT04375150 | Renal Cell Carc... | Tyrosine kinase... Immuno-oncology... | 20 Years - | Pfizer | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | NCT04195750 | Carcinoma, Rena... | Belzutifan Everolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | NCT02646748 | Colorectal Canc... Endometrial Can... Melanoma Head and Neck C... Lung Cancer MMR-deficient T... Breast Cancer Pancreatic Canc... Renal Cell Carc... Solid Tumors UC (Urothelial ... | Pembrolizumab itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| ITIL-306 in Advanced Solid Tumors | NCT05397093 | Epithelial Ovar... Non-small Cell ... Renal Cell Carc... | ITIL-306 | 18 Years - | Instil Bio | |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | NCT03549000 | Non-small Cell ... Triple Negative... Pancreatic Duct... Colorectal Canc... Ovarian Cancer Renal Cell Carc... Metastatic Cast... | NZV930 PDR001 NIR178 | 18 Years - | Novartis | |
| FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS | NCT03955393 | Renal Cell Carc... | 18F-FAZA PET IM... | 18 Years - | IRCCS San Raffaele | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | NCT03961698 | Breast Cancer Renal Cell Carc... | IPI-549 (eganel... Atezolizumab nab-paclitaxel Bevacizumab | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | NCT02178722 | Microsatellite-... Endometrial Can... Head and Neck C... Hepatocellular ... Gastric Cancer Lung Cancer Lymphoma Renal Cell Carc... Ovarian Cancer Solid Tumors UC (Urothelial ... Melanoma Bladder Cancer Triple Negative... | MK-3475 INCB024360 | 18 Years - | Incyte Corporation | |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | NCT05891171 | Advanced Cancer Advanced Malign... Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Gastroesophagea... Head and Neck S... Non-Small Cell ... Ovarian Cancer Renal Cell Carc... Triple Negative... | AB598 Zimberelimab Carboplatin Pemetrexed Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | NCT04375150 | Renal Cell Carc... | Tyrosine kinase... Immuno-oncology... | 20 Years - | Pfizer | |
| LITT and Pembrolizumab in Recurrent Brain Metastasis | NCT04187872 | Melanoma Non-small Cell ... Renal Cell Carc... Small-cell Lung... Head and Neck S... Classical Hodgk... Primary Mediast... Urothelial Carc... Microsatellite ... Gastric Cancer Esophageal Canc... Cervical Cancer Hepatocellular ... Merkel Cell Car... Brain Metastase... | LITT + Pembroli... | 18 Years - 100 Years | University of Florida | |
| Avelumab Program Rollover Study | NCT03815643 | Solid Tumors | Avelumab | 18 Years - | EMD Serono | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) | NCT01235962 | Renal Cell Carc... Cancer | pazopanib placebo pazopanib placebo | 18 Years - | Novartis | |
| "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)" | NCT05410509 | Renal Cell Carc... | Trans-arterial ... | 18 Years - | University of Alabama at Birmingham | |
| A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | NCT03241173 | Advanced Malign... | INCAGN01949 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. | NCT00199888 | Cancer of Kidne... Kidney Cancer Renal Cancer Neoplasms, Kidn... Renal Neoplasms Renal Cell Carc... Clear Cell Rena... | 124-Iodine-cG25... | 18 Years - | Ludwig Institute for Cancer Research | |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | NCT03260894 | Renal Cell Carc... | Pembrolizumab Epacadostat Sunitinib Pazopanib | 18 Years - | Incyte Corporation | |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | NCT03277352 | Advanced Malign... Metastatic Canc... | INCAGN01876 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | NCT03260894 | Renal Cell Carc... | Pembrolizumab Epacadostat Sunitinib Pazopanib | 18 Years - | Incyte Corporation | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Phase 2 Study in Patients With MiT Tumors | NCT00557609 | Renal Cell Carc... Alveolar Soft P... Clear Cell Sarc... | ARQ 197 | 13 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | NCT02811861 | Renal Cell Carc... | Lenvatinib Everolimus Pembrolizumab Sunitinib | 18 Years - | Eisai Inc. | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS | NCT03955393 | Renal Cell Carc... | 18F-FAZA PET IM... | 18 Years - | IRCCS San Raffaele | |
| Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma | NCT00520533 | Renal Cell Carc... | Chimeric monocl... Sunitinib malat... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) | NCT01235962 | Renal Cell Carc... Cancer | pazopanib placebo pazopanib placebo | 18 Years - | Novartis | |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | NCT04489771 | Carcinoma, Rena... | Belzutifan | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
